Humacyte Inc. (HUMA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

The Roarable RQD rating is 31 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Per the Roarable RQD rating, the five pillars score as follows:

• Fundamental Cash Engine: 4 / 20. The pillar reflects ROIC of -35% and an FCF yield of 0%. For an investor, this means the business is not currently generating returns on capital or free cash flow, so value depends on future cash generation that the source data does not project.
• Whale 13F Flow: 11 / 20. The pillar covers institutional accumulation and options positioning. Because the holders section is empty in the source data, the specific institutional activity behind this score cannot be verified here.
• Insider Conviction: 3 / 20. The pillar covers SEC Form 4 and Congressional PTR cluster flow. This is the second-weakest pillar and signals limited insider-side conviction, though the underlying trade detail is not in the source data.
• Macro Regime Fit: 5 / 20. The pillar reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broad market, offering no defensive cushion.
• Forensic Balance Sheet: 8 / 20. The pillar reflects an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. The weak Piotroski reading indicates poor financial-health signals across the nine-point checklist.

For a prospective investor evaluating the stock today, the rating points toward elevated forensic and fundamental risk. Upside drivers would have to come from outside the current cash engine, such as catalysts or sentiment shifts, rather than from reported earnings. Valuation tradeoffs are severe: the market capitalization is $130.5M against FY 2025 revenue of $2.0M and an operating loss of $-108.1M. The RQD rating is a model output and does not constitute personalized financial advice.

Per the market data, gross margin is -30%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with a Debt/Equity ratio of 0.5. Reported cash rose from $44.9M in FY 2024 to $50.5M in FY 2025 while free cash flow remained negative in each reported year. The balance sheet posture therefore depends on continued access to funding against sustained cash burn.

Per the news wire, the items split into risk and catalyst signals:

• RED — RISK WATCH: An item reports analyst target cuts, with fair value moving lower.
• GREEN — CATALYST: An item reports that 49 hospitals ordered the bioengineered blood vessel and that several surgeons submitted patient case studies for presentations.
• GREEN — CATALYST: An item reports that H.C. Wainwright reiterated a Buy after the hospital ordering news.
• YELLOW — MARKET WIRE: Items report market action and a StoneX price target reiterated at $1.
• YELLOW — MARKET WIRE: Items cover the options chain and a session in which the stock slid as the market rose.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

• What is the company's revenue model and product base, given that the profile and sources do not describe its products or customers?
• Are the hospital orders and surgeon case studies reflected in the reported FY 2025 revenue of $2.0M, and what is the forward revenue trajectory?
• What is the funding runway given cash of $50.5M against FY 2025 free cash flow of $-105.9M?
• Which institutional and insider holders are behind the whale and insider pillar scores, since the holders section is empty?
• What drove the analyst target cuts flagged as a RED risk item, and what is the current consensus rating?